Celestra (A352770) Stock Overview
A biotechnology company, provides genome-based cancer and disease diagnostic solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A352770 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Celestra Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,250.00 |
| 52 Week High | ₩25,410.00 |
| 52 Week Low | ₩4,245.00 |
| Beta | 1.15 |
| 1 Month Change | 0% |
| 3 Month Change | -20.63% |
| 1 Year Change | -76.46% |
| 3 Year Change | -92.81% |
| 5 Year Change | n/a |
| Change since IPO | -97.24% |
Recent News & Updates
Shareholder Returns
| A352770 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0% | 3.6% | 4.2% |
| 1Y | -76.5% | 45.5% | 71.0% |
Return vs Industry: A352770 underperformed the KR Biotechs industry which returned 18% over the past year.
Return vs Market: A352770 underperformed the KR Market which returned 5.9% over the past year.
Price Volatility
| A352770 volatility | |
|---|---|
| A352770 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A352770's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A352770's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 48 | ByungChul Kim | www.celestra.co.kr |
Celestra Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to precision medicine information with bioinformatics and the detection of various gene mutations; and BioViewCCBS, a scanning platform that helps in capturing cells inside the sample in 3D and in finding and analyzing CTC inside the sample.
Celestra Inc. Fundamentals Summary
| A352770 fundamental statistics | |
|---|---|
| Market cap | ₩13.46b |
| Earnings (TTM) | -₩54.83b |
| Revenue (TTM) | ₩6.00b |
Is A352770 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A352770 income statement (TTM) | |
|---|---|
| Revenue | ₩6.00b |
| Cost of Revenue | ₩7.86b |
| Gross Profit | -₩1.87b |
| Other Expenses | ₩52.96b |
| Earnings | -₩54.83b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -21.39k |
| Gross Margin | -31.16% |
| Net Profit Margin | -914.51% |
| Debt/Equity Ratio | -189.7% |
How did A352770 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/01 09:05 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celestra Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.